v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Dec. 31, 2024
Current assets:      
Cash and cash equivalents $ 2,823 $ 3,240 $ 3,232
Accounts receivable 0 1,000 556
Prepaid expenses 255 384 421
Other current assets 11 11 16
Total current assets 3,089 4,635 4,225
Property and equipment, net 66 0  
Other investment 5,350 5,350 5,350
Total assets 8,505 9,985 9,575
Current liabilities:      
Accounts payable 457 508 390
Accrued research and development costs 148 198 52
Accrued expenses and other current liabilities 1,109 194 283
Total current liabilities 1,714 900 725
Commitments and contingencies (Note 6) 0 0 0
Stockholders' equity      
Preferred stock, no par value, 100,000,000 shares authorized and 351,037 shares of Series A convertible preferred stock issued and outstanding at March 31, 2026 and December 31, 2025 0 0 0
Common stock, no par value, 400,000,000 shares authorized at March 31, 2026 and December 31, 2025; 4,330,314 and 3,925,314 shares issued at March 31, 2026 and December 31, 2025, respectively; 4,241,260 and 3,821,236 shares outstanding at March 31, 2026 and December 31, 2025, respectively 0 0 0
Paid-in capital 280,988 280,105 276,342
Accumulated deficit (274,197) (271,020) (267,492)
Total stockholders' equity 6,791 9,085 8,850
Total liabilities and stockholders' equity $ 8,505 $ 9,985 $ 9,575